Publications While At Healthpartners
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
Diabetes, Obesity & Metabolism.
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring
Diabetes/Metabolism Research and Reviews.
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial
Efficacy and safety of LixiLan vs. insulin glargine according to baseline characteristics in patients with type 2 diabetes from the LixiLan-L Trial [abstract 1018-P]
Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]
Map of science